Krystal Biotech (KRYS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $1.79
- Estimate
- $1.91
- Surprise
- -6.5%
- Revenue (period 2026-06-30)
- $119.2M
- Score today
- 6.2/10
Revenue source: xbrl.
How the report landed
Krystal Biotech (KRYS) missed the $1.91 estimate with adjusted EPS of $1.79 — a clear 6.5% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates KRYS Buy (Wait) at 6.2/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -6.5% surprise compares with a +41.3% four-quarter average. Next scheduled report: 2026-11-02.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.1 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: VYJUVEK
- Thin upside margin: 3.2%
- Expensive valuation
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $330.69
- Entry target
- $302.77
- Price target
- $341.14
- Stop
- $281.75
- Upside to target
- +3.2%
- Reward-to-risk
- 0.5:1
At 40.2× trailing and 34.7× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
KRYS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $9.51B
- P/E (fwd)
- 34.7
- P/E (ttm)
- 40.2
- 52-week range
- $183.03–$382.54
- Off 52-week high
- 13.6%
- RSI (14)
- 41
- Volume vs avg
- 0.91×
- Score today
- 6.2/10